Publication Relating to Transparency Notifications

Why It Matters

A 10% shareholder can influence Nyxoah’s board decisions and strategic direction, potentially affecting its valuation and market perception. The disclosure also underscores strict European transparency rules for listed companies.

Key Takeaways

• Robert Taub holds 10.14% of Nyxoah voting rights.
• Robelga SRL crossed 3% threshold on Dec 30, 2025.
• Total disclosed holdings amount to 4,360,800 votes.
• Warrants grant additional 25,000 voting rights to Taub.
• Notification complies with Belgian Act of 2007.

Pulse Analysis

Nyxoah SA, a specialist in implantable sleep‑apnea devices, has attracted heightened investor scrutiny after Robert Taub and his vehicle Robelga SRL collectively surpassed the 3% ownership trigger under Belgian law. The transparency notification, filed on March 19, 2026, details a combined 10.14% stake, positioning Taub as a significant minority shareholder. Such a concentration can reshape voting dynamics, especially in a company where strategic R&D pipelines and regulatory approvals drive long‑term value. Analysts will monitor whether this influence translates into board representation or shifts in corporate strategy, given Nyxoah’s ongoing expansion into new markets and product iterations.

The regulatory backdrop is equally important. Belgium’s Act of 2 May 2007 mandates prompt disclosure when shareholders cross predefined thresholds, fostering market transparency and protecting minority investors. By adhering to these rules, Nyxoah demonstrates compliance and reinforces investor confidence. However, the presence of warrants—granting Taub an extra 25,000 voting rights—adds a layer of potential future dilution. Market participants should assess how these instruments might affect voting power if exercised, especially as Nyxoah approaches key clinical milestones.

From a broader market perspective, a 10% stake by an activist‑oriented investor can signal confidence in the company’s growth prospects or a desire to steer strategic pivots. For Nyxoah, which operates in the competitive medical‑device sector, any shift in governance could impact partnership negotiations, capital allocation, and product rollout timelines. Investors should therefore weigh the implications of this ownership change alongside the company’s pipeline progress and the evolving regulatory environment for sleep‑apnea therapies.